com_NN
Therapy_NN
area_NN
review_NN
sales_NN
and_CC
further_JJ
development_NOMZ
of_PIN
Nexium_NN
._.
Cardiovascular_NN
CV_NN
We_FPP1
are_VPRT [BEMA]
a_DT
world_NN
leader_NN
in_PIN
cardiovascular_JJ
40_CD
%_NN
of_PIN
adults_NN
in_PIN
the_DT
western_JJ
world_NN
regularly_RB
medicines_NN
,_,
with_PIN
over_IN
40_CD
years_NN
experience_NN
experience_NN
heartburn_NN
and_CC
between_PIN
10_CD
and_CC
and_CC
a_DT
powerful_JJ
range_NN
of_PIN
products_NN
._.
Backed_NN
20_CD
%_NN
have_VPRT
gastro-oesophageal_JJ
reflux_NN
by_PIN
our_FPP1
quality_NOMZ
research_NN
,_,
we_FPP1
aim_VPRT
to_TO
build_VB
disease_NN
GERD_NN
._.
The_DT
prevalence_NN
of_PIN
GERD_NN
on_PIN
our_FPP1
strong_JJ
position_NOMZ
,_,
focusing_VBG [PRESP]
on_PIN
in_PIN
Asia_NN
is_VPRT [BEMA]
lower_PRED
,_,
but_CC
increasing_VBG
._.
important_JJ
areas_NN
of_PIN
need_NN
such_JJ
as_IN
hypertension_NN
,_,
diabetes_NN
,_,
dyslipidemia_NN
Nexium_NN
continues_VPRT
to_TO
establish_VB [PRIV]
a_DT
new_JJ
and_CC
thrombosis_NN
._.
improved_VBN
treatment_NOMZ
standard_NN
and_CC
this_DEMP
was_VBD [PASS]
reflected_VBN [PRIV]
in_PIN
its_PIT
global_JJ
sales_NN
,_,
which_WDT [SERE]
CV_NN
disease_NN
accounts_NN
for_PIN
17_CD
million_CD
exceeded_VBD
$_$
3.8_CD
billion_CD
in_PIN
2004_CD
._.
First_NN
deaths_NN
worldwide_JJ
each_QUAN
year_NN
,_,
making_VBG [PRESP]
it_PIT
launched_VBD
in_PIN
Sweden_NN
in_PIN
August_NN
2000_CD
,_,
the_DT
greatest_JJ
risk_NN
to_PIN
life_NN
for_PIN
most_EMPH
adults_NN
._.
it_PIT
is_VPRT [BEMA]
now_TIME
available_PRED
in_PIN
approximately_RB
100_CD
markets_NN
,_,
including_VBG [PRESP]
the_DT
US_FPP1
,_,
Canada_NN
and_PHC
Crestor_NN
,_,
our_FPP1
new_JJ
statin_NN
for_PIN
controlling_VBG
all_QUAN
European_JJ
countries_NN
._.
It_PIT
has_VPRT [PEAS]
been_VBN
well_RB
cholesterol_NN
levels_NN
,_,
is_VPRT [SPAU] [PASS]
now_TIME
approved_VBN
in_PIN
67_CD
received_VBN
by_PIN
patients_NN
and_PHC
physicians_NN
alike_RB
markets_NN
and_CC
launched_VBN
in_PIN
56_CD
,_,
including_VBG [PRESP]
the_DT
and_CC
close_VB
to_PIN
250_CD
million_CD
patient_JJ
treatments_NOMZ
US_FPP1
,_,
Canada_NN
and_CC
the_DT
majority_NOMZ
of_PIN
EU_NN
countries_NN
._.
had_VBD [PEAS]
been_VBN [BYPA]
administered_VBN
by_PIN
the_DT
end_NN
of_PIN
By_PIN
the_DT
end_NN
of_PIN
2004_CD
,_,
over_IN
15_CD
million_CD
2004_CD
._.
Its_PIT
strong_JJ
performance_NN
in_PIN
the_DT
US_FPP1
prescriptions_NOMZ
had_VBD [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
for_PIN [STPR]
,_,
and_ANDC
over_IN
makes_VPRT
Nexium_NN
the_DT
most_EMPH
successful_JJ
four_CD
million_CD
patients_NN
treated_VBN [WZPAST]
with_PIN
Crestor_NN
._.
Public_NN
Citizen_NN
,_,
a_DT
US_FPP1
consumer_NN
interest_NN
organization_NOMZ
,_,
continued_VBD
to_TO
raise_VB
allegations_NOMZ
An_DT
injectable_JJ
intravenous_JJ
formulation_NOMZ
concerning_VBG [WZPRES]
the_DT
safety_NN
of_PIN
Crestor_NN
._.
of_PIN
Nexium_NN
is_VPRT [SPAU] [PASS]
now_TIME
approved_VBN
in_PIN
47_CD
Clinical_JJ
trials_NN
experience_NN
and_CC
post-marketing_JJ
countries_NN
,_,
for_PIN
use_NN
when_RB
an_DT
oral_JJ
treatment_NOMZ
surveillance_NN
continue_VPRT
to_TO
support_VB
our_FPP1
belief_NN
of_PIN
GERD_NN
is_VPRT [BEMA]
not_XX0
appropriate_PRED
._.
In_PIN
September_NN
that_TOBJ
Crestor_NN
has_VPRT
a_DT
safety_NN
profile_NN
in_PIN
line_NN
with_PIN
2004_CD
,_,
approval_NN
was_VBD [PASS]
granted_VBN [SUAV]
through_PIN
the_DT
other_JJ
marketed_VBN
statins_NN
._.
Clinical_JJ
trial_NN
and_PHC
postEU_NN
Mutual_NN
Recognition_NOMZ
Procedure_NN
for_PIN
the_DT
marketing_GER
data_NN
for_PIN
Crestor_NN
are_VPRT
publicly_RB
use_NN
of_PIN
Nexium_NN
in_PIN
the_DT
healing_GER
and_CC
available_JJ
on_PIN
a_DT
dedicated_JJ
website_NN
,_,
prevention_NOMZ
of_PIN
ulcers_NN
associated_VBN [WZPAST]
with_PIN [STPR]
._.
com_NN
,_,
which_WDT [SERE]
we_FPP1
non-steroidal_JJ
anti-inflammatory_JJ
launched_VBN
in_PIN
September_NN
2004_CD
._.
drug_NN
NSAID_NN
therapy_NN
._.
Approval_NN
for_PIN
the_DT
reduction_NOMZ
in_PIN
occurrence_NN
of_PIN
gastric_JJ
ulcers_NN
2004_CD
saw_VBD [PRIV]
the_DT
first_JJ
launches_NN
of_PIN
Exanta_NN
,_,
associated_VBN [PASTP]
with_PIN
continuous_JJ
NSAID_NN
our_FPP1
new_JJ
oral_JJ
anti-coagulant_JJ
,_,
for_PIN
use_NN
therapy_NN
in_PIN
patients_NN
at_PIN
risk_NN
for_PIN
developing_VBG
in_PIN
preventing_VBG
blood_NN
clots_NN
following_VBG [WZPRES]
gastric_JJ
ulcers_NN
was_VBD [PASS]
granted_VBN [SUAV]
in_PIN
the_DT
US_FPP1
orthopaedic_NN
surgery_NN
in_PIN
10_CD
countries_NN
._.
In_PIN
October_NN
2004_CD
,_,
the_DT
FDA_NN
confirmed_VBD [PUBV]
that_THVC
it_PIT
did_VBD
not_XX0
approve_VB
Exanta_NN
for_PIN
Infection_NOMZ
marketing_GER
in_PIN
the_DT
US_FPP1
for_PIN
any_QUAN
of_PIN
the_DT
World_NN
demand_NN
for_PIN
antibiotics_NN
remains_VPRT
indications_NOMZ
sought_VBD
._.
Discussions_NN
are_VPRT [BEMA]
high_JJ
due_JJ
to_TO
escalating_VBG
resistance_NN
and_CC
ongoing_JJ
with_PIN
the_DT
FDA_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
increased_VBN
risk_NN
of_PIN
serious_JJ
infections_NOMZ
._.
whether_IN
there_EX
is_VPRT
now_TIME
a_DT
realistic_JJ
prospect_NN
Infectious_JJ
diseases_NN
cause_VPRT
more_EMPH
than_PIN
of_PIN
bringing_VBG
Exanta_NN
to_PIN
the_DT
US_FPP1
market_NN
._.
At_PIN
the_DT
end_NN
of_PIN
2004_CD
,_,
we_FPP1
received_VBD
approval_NN
2004_CD
again_TIME
saw_VBD [PRIV]
steady_JJ
sales_NN
growth_NN
in_PIN
the_DT
EU_NN
,_,
and_ANDC
an_DT
approvable_JJ
letter_NN
from_PIN
globally_RB
for_PIN
Merrem_NN
,_,
our_FPP1
antibiotic_JJ
for_PIN
the_DT
the_DT
FDA_NN
,_,
for_PIN
the_DT
use_NN
of_PIN
Atacand_NN
in_PIN
heart_NN
treatment_NOMZ
of_PIN
serious_JJ
,_,
hospital-acquired_JJ
failure_NN
,_,
based_VBN [PASTP]
on_PIN
the_DT
results_NN
of_PIN
a_DT
infections_NOMZ
._.
A_DT
Supplementary_NN
New_NN
Drug_NN
comprehensive_JJ
clinical_JJ
study_NN
program_NN
,_,
Application_NOMZ
was_VBD [PASS]
filed_VBN
in_PIN
the_DT
US_FPP1
in_PIN
2004_CD
CHARM_NN
,_,
which_WDT [SERE]
showed_VBD [PRIV]
significant_JJ
aimed_VBN
at_PIN
securing_VBG
an_DT
indication_NOMZ
for_PIN
skin_NN
reduction_NOMZ
in_PIN
the_DT
number_NN
of_PIN
deaths_NN
and_CC
and_CC
skin_NN
structure_NN
infections_NOMZ
in_PIN
2005_CD
._.
hospitalisations_NOMZ
for_PIN
heart_NN
failure_NN
in_PIN
patients_NN
treated_VBN [WZPAST]
with_PIN
Atacand_NN
._.
Work_NN
continues_VPRT
at_PIN
our_FPP1
research_NN
facility_NOMZ
in_PIN
Bangalore_NN
,_,
India_NN
where_RB
we_FPP1
are_VPRT [PASS]
focused_VBN
With_PIN
sales_NN
again_TIME
exceeding_VBG
$_$
1_CD
billion_CD
on_PIN
finding_VBG [PRIV]
a_DT
new_JJ
treatment_NOMZ
for_PIN
tuberculosis_NN
in_PIN
2004_CD
,_,
Seloken_NN
Toprol-XL_NN
is_VPRT [BEMA]
the_DT
worlds_NN
TB_NN
,_,
the_DT
single_JJ
largest_JJ
cause_NN
of_PIN
adult_NN
leading_VBG [WZPRES]
product_NN
by_PIN
sales_NN
in_PIN
the_DT
beta_JJ
death_NN
from_PIN
infectious_JJ
disease_NN
in_PIN
the_DT
world_NN
._.
blocker_NN
plain_NN
and_CC
in_PIN
combination_NOMZ
with_PIN
diuretic_JJ
class_NN
._.
Neuroscience_NN
We_FPP1
aim_VPRT
to_TO
deliver_VB
a_DT
range_NN
of_PIN
life-changing_JJ
Gastrointestinal_NN
GI_NN
medicines_NN
in_PIN
three_CD
key_JJ
areas_NN
of_PIN
psychiatry_NN
,_,
We_FPP1
aim_VPRT
to_TO
maintain_VB [PUBV]
our_FPP1
number_NN
one_CD
position_NOMZ
analgesia_NN
and_PHC
neurology_NN
,_,
and_ANDC
by_PIN
maintaining_VBG [PUBV]
in_PIN
GI_NN
treatments_NOMZ
through_PIN
driving_VBG
continued_VBN
our_FPP1
world_NN
leading_VBG [WZPRES]
position_NOMZ
in_PIN
anaesthesia_NN
._.
